Athenagen Announces Publication of Results From a Proof-of-Concept Trial of Its Novel alpha-7 Nicotinic Receptor Agonist in Schizophrenia: Financial N

Athenagen Announces Publication of Results From a Proof-of-Concept Trial of Its Novel alpha-7 Nicotinic Receptor Agonist in Schizophrenia: Financial News - Yahoo! Finance: "'We are encouraged by these data demonstrating utility of GTS-21 for cognition enhancement in schizophrenia,' stated Henry Hsu, M.D., Chief Medical Officer of Athenagen. 'Taken together with Phase 1 data demonstrating safety and also cognition enhancement in healthy volunteers, we intend to further study GTS-21 in diseases associated with cognitive deficiency, such as Alzheimer's disease, Mild Cognitive Impairment, and Attention Deficit Hyperactivity Disorder.'"